IPSEN (OTCMKTS:IPSEY) Reaches New 1-Year High - What's Next?

Key Points

• IPSEN's shares hit a new 52-week high of $51.10 mid-day, trading up about 3.1% with 1,519 shares and sitting above its 50-day ($46.75) and 200-day ($40.60) moving averages.
• Analysts are mixed — Deutsche Bank reissued a "buy", UBS downgraded the stock to "hold", and the consensus rating is an average of Hold (1 Buy, 1 Hold, 1 Sell).
• Ipsen is a global biopharmaceutical company focused on oncology, neuroscience and rare diseases, with key products such as Cabometyx and Decapeptyl.

IPSEN (OTCMKTS:IPSEY - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $51.10 and last traded at $51.10, with a volume of 1519 shares traded. The stock had previously closed at $49.0850.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on IPSEY shares. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of IPSEN in a report on Tuesday, April 14th. UBS Group lowered shares of IPSEN from a "strong-buy" rating to a "hold" rating in a report on Thursday, January 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold".

IPSEN Trading Up 3.1%

The firm's fifty day moving average price is $46.75 and its two-hundred day moving average price is $40.60.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company's oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.